NRXS News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

NR

Mkt Cap

$96.9M

Volume

227.46K

Next Earnings

November 9th

Loading chart

NR

NRXSNeuraxis, Inc.

NRXS

Pay with—

Available Balance0.00

NR

Mkt Cap

$97.2M

Volume

227.46K

Next Earnings

November 9th

Chart Financials Earnings News About Insider Filings

Is Kodak having a "Kodak moment?" 2 watchlist stocks.Eastman Kodak (KODK) shows operational improvement with 18% revenue growth and expanding margins, but analysts maintain a Neutral stance pending consistent FCF execution. NeurAxis (NRXS) demonstrates strong revenue growth and pricing power in neuromodulation products, but high valuation and operating losses keep it on the sidelines at Neutral.Zacks Investment Research · Sep 12, 2026

NeurAxis to Host First Quarter 2026 Results and Business Update Call on Tuesday, May 12, 2026NeurAxis, Inc. (NYSE American: NRXS), a medical technology company specializing in neuromodulation therapies, announced it will report Q1 2026 financial results on May 12, 2026, before market open, followed by a conference call at 9:00 am ET. The company commercializes IB-Stim, its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, which is FDA cleared for treating functional abdominal pain associated with IBS and functional dyspepsia in patients 8 years and older.GlobeNewswire Inc. · May 5, 2026

NeurAxis Awarded First Ever FDA Clearance for the Treatment of Pain in Functional Dyspepsia (FD) with associated Nausea Symptoms in the Adult Patient PopulationNeurAxis received FDA 510(k) clearance for its percutaneous electrical nerve field stimulation (PENFS) technology to treat functional dyspepsia and related nausea symptoms in patients aged 8 years and older, marking the first FDA approval for this condition in adults.GlobeNewswire Inc. · Oct 24, 2025

NeurAxis to Host First Quarter 2025 Results and Business Update Call on Monday, May 12, 2025NeurAxis, Inc. will report its Q1 2025 financial results on May 12, 2025, before market open, and host a conference call on the same day at 9:00 am ET to review the results.GlobeNewswire Inc. · May 5, 2025

NeurAxis to Host Fourth Quarter and Full Year 2024 Results and Business Update Call on Thursday, March 20, 2025NeurAxis, a medical technology company, will report its Q4 and fiscal year 2024 financial results on March 20, 2025, and host a conference call to discuss the results.GlobeNewswire Inc. · Mar 12, 2025

UPDATE - NeurAxis Announces New Medical Policy Coverage with a Prominent Insurer for Over Five Million Lives Across Multiple StatesNeurAxis, a medical technology company, announced that its Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, IB-Stim, has received medical policy coverage from a prominent insurer with approximately 5.1 million members across 13 states.GlobeNewswire Inc. · Jan 21, 2025

NeurAxis Inc. Issues Letter to ShareholdersNeurAxis, a medical technology company, announced its achievements in 2024, including the growth of IB-Stim for pediatric irritable bowel syndrome and the commercialization of RED, a screening tool for chronic constipation. The company also highlighted its plans to submit for expanded indications in 2025 and its focus on revenue growth, cost management, and balance sheet strengthening.GlobeNewswire Inc. · Jan 13, 2025

NeurAxis Inc. to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025NeurAxis, a medical technology company, announced that CEO Brian Carrico will participate in a webcasted company presentation at the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025. The company is focused on neuromodulation therapies to address chronic and debilitating conditions in children and adults.GlobeNewswire Inc. · Jan 6, 2025

NeurAxis to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024NeurAxis, Inc., a medical technology company focused on neuromodulation therapies, will participate in a webcasted presentation and host one-on-one meetings at the Lytham Partners Fall 2024 Investor Conference.GlobeNewswire Inc. · Sep 19, 2024

NeurAxis Announces BCBS of Vermont Medical Policy Coverage for PENFS, effective October 1st 2024NeurAxis, a medical technology company, announced that its IB-Stim™ device has received medical policy coverage from Blue Cross Blue Shield of Vermont, expanding its national coverage to around 23 million lives. The company aims to achieve coverage for at least 50 million lives by the end of 2024.GlobeNewswire Inc. · Aug 13, 2024

to start trading

NR

NRXSNeuraxis, Inc.

NRXS

Pay with—

Available Balance0.00

Your PositionYou don't own any NRXS yet.

Related Tickers

Earnings